TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03366467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SADE
Description: The SADE: the sensory stimuli addressed are visual and auditory, as follows: (i) Visual sensation. All ceiling fluorescent lighting are removed. The adapted lighting consisted of slow-moving, repetitive visual color effects created by a projector, in the child's visual field. (ii) Auditory stimuli include rhythmic music, which was heard via loudspeakers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RDE
Description: The RDE utilized fluorescent lighting on the ceiling, without special visual effects and without music stimulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RDE
Description: The RDE utilized fluorescent lighting on the ceiling, without special visual effects and without music stimulation.
Study: NCT06023615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth app/dashboard
Description: In the interventional group, the subject would receive the standard care that is provided to all post-transplant kidney recipients plus an additional remote monitoring system and follow-up by utilizing an app known as the mHealth app/dashboard. This app is integrated with home-based monitoring of blood pressures, glucoses, and pharmacist-led scheduled televisits.
Study: NCT05443711

Intervention type: OTHER
Intervention: No intervention, observational study
Description: No intervention, observational study

Intervention type: OTHER
Intervention: No intervention, observational study
Description: No intervention, observational study
Study: NCT05325840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music terapy
Description: The aim of this study was to examine the effects of the music concert applied during the nonstress test procedure on the health of the fetus, the anxiety level of the pregnant woman and blood pressure.
Study: NCT06226584

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multiple-strain probiotics
Description: Juice HA capsule which contains more than one strain of probiotics
Study: NCT05683119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and blood draw
Description: This project intends to investigate the effects of circulating fluctuations in oestradiol and progesterone, experienced during the menstrual cycle \[MC\] and oral contraceptive pill \[OCP\] use, on aspects of exercise physiology and athletic performance in female athletes. This research aims to determine if a particular hormonal profile affects physiological functioning (e.g., muscle strength, maximum oxygen uptake) and/or athletic performance in female athletes. The intervention will include a stretching regimen, balance test, push-ups, agility test, handgrip muscle test, vertical jump, flexibility test, cycling protocol, blood sample and height/ weight measurements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and blood draw
Description: This project intends to investigate the effects of circulating fluctuations in oestradiol and progesterone, experienced during the menstrual cycle \[MC\] and oral contraceptive pill \[OCP\] use, on aspects of exercise physiology and athletic performance in female athletes. This research aims to determine if a particular hormonal profile affects physiological functioning (e.g., muscle strength, maximum oxygen uptake) and/or athletic performance in female athletes. The intervention will include a stretching regimen, balance test, push-ups, agility test, handgrip muscle test, vertical jump, flexibility test, cycling protocol, blood sample and height/ weight measurements.
Study: NCT04339699

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NobleStitch™EL Suture Mediated Closure System
Description: Percutaneous closure of Patent Foramen Ovale (PFO) using NobleStitch™EL suture Medicate Closure System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amplatzer PFO Occluder
Description: Percutaneous closure of Patent Foramen Ovale (PFO) using Amplatzer PFO Occluder
Study: NCT05578599

Intervention type: DEVICE
Group type: OTHER
Intervention: Swiftsure CCS device
Description: The Swiftsure CSS device will be used twice per patient in addition to standard oral health care procedures among intubated adult patients undergoing mechanical ventilation in the ICU.
Study: NCT05706584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control grup (skills lab.) and experimental group (mateverse skill lab.)
Description: The universe of the study consists of students (N: 190) who took a pediatric nursing course in the 3rd year of the Teaching Department at Istanbul Medipol University. The sample of the study will consist of the students who took the 3rd year child health and diseases nursing course in the nursing department, accepted the study, and met the study criteria. It will try to reach the universe where the sample selection of the research will not be made. With the simple randomization method, students will be assigned to the experimental and control groups. Even the last digit of the student number will be randomized to the experimental group and odd ones will be randomized to the control group
Study: NCT05405738

Intervention type: PROCEDURE
Intervention: 2 flap palatoplasty technique
Description: cleft palate repair by 2 flap palatoplasty technique

Intervention type: OTHER
Intervention: normal group
Description: control normal group
Study: NCT04980677

Intervention type: DEVICE
Group type: OTHER
Intervention: Tangiball
Description: To enable baseline scores comparison, children will be matched according to age and score on the four-strand Hands-On assessment tool which takes 30 minutes to complete. Children will then play with the Smart Toy during a 20 minute session. Sessions will be recorded using an SD card within the Smart Toy which captures information on user speed and accuracy of placement of the detachable segments of the toy when placed into the main hub of the toy, allowing comparison between neuro-typical children and children with Autism. The intervention will run either in clinic (preferred option) or in children's homes-and in this case will be sent to them via post with the Standard Operating Procedure which can then be employed when children are taking part in the intervention via online video link (not recorded).
Study: NCT04785274

Intervention type: DEVICE
Intervention: non-invasive hemoglobin (SpHb)
Description: hemoglobin measuring device

Intervention type: DEVICE
Intervention: non-invasive hemoglobin (SpHb)
Description: hemoglobin measuring device
Study: NCT05678556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: all2GETHER
Description: all2GETHER is an HIV prevention and relationship education program designed for young MSM and other individuals who have sex, date, and are in relationships with MSM. all2GEHTER consists of 3 online didactic skills modules that include videos, activities, and other self-paced education components and 2 videoconference-based skills coaching sessions The 3 online modules focus on developmental skills related to sexual health and relationship functioning, including HIV and STI prevention in couples, effective communication skills, coping skills for LGBTQ and relationship stress, problem-solving and acceptance. Individualized couple sessions led by facilitators focus on implementation of skills specific to the needs of each couple.
Study: NCT04909775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg per cycle, IV on day 1 of 3-week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70mg/m2 IV on Day 1 of 3-week, for 4 cycles. Dose fractionation is permissible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2, Day 1 and Day 8 of 3-week, for 4 cycles
Study: NCT05096507

Intervention type: PROCEDURE
Intervention: Hip fracture Surgery (Primary)
Description: Surgery for primary hip fracture requiring general or neuro-axial anaesthesia
Study: NCT05405738

Intervention type: PROCEDURE
Intervention: Furlow with buccinator technique
Description: cleft palate repair by Furlow with buccinator technique
Study: NCT04694313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPM
Description: Simultaneous MEG SQUID + SEEG acquisition followed by a simultaneous MEG OPM + SEEG acquisition.
Study: NCT05537571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN360
Description: SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN360
Description: SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN360
Description: SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride, solution for injection
Study: NCT06593418

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Stereotactic body radiation therapy, which delivers precise, high-dose radiation non-invasively to generate thermal scarring to myocardial targets causing VT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Stereotactic body radiation therapy, which delivers precise, high-dose radiation non-invasively to generate thermal scarring to myocardial targets causing VT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Stereotactic body radiation therapy, which delivers precise, high-dose radiation non-invasively to generate thermal scarring to myocardial targets causing VT
Study: NCT05284344

Intervention type: DRUG
Intervention: Anti-Diabetics
Description: The anti-diabetic treatments include insulin glargine, insulin aspart, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, metformin, sulfonylureas and/or gliclazide. Therapeutic dose of each drug follows recommendation by the treating doctor.
Study: NCT05407350

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound, Colonoscopy, MRE
Description: After the initiation of an established treatment of known efficacy for CD (biologic agents including infliximab, adalimumab, ustekinumab or vedolizumab either with or without corticosteroids), repeat IC and MRE will occur at Week 30 (± 6 weeks) (6-9 months); the IUS, IC, and MRE examinations will occur within a 4-week window and with no intervening change in medical therapy. All imaging data will be captured electronically (IUS and MRE with Digital Imaging and Communications in Medicine \[DICOM\] images, and IC with video recordings) for central, blinded reading. Two biopsies will be collected from each segment of the bowel (rectum, sigmoid, descending, transverse, ascending and terminal ileum) during IC, fixed in formalin collection containers, and shipped for histopathology processing and evaluation.
Study: NCT06625307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0537-1482
Description: Administered via subcutaneous route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0537-1482
Description: Administered via subcutaneous route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0537-1482
Description: Administered via subcutaneous route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0537-1482
Description: Administered via subcutaneous route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0537-1482
Description: Administered via subcutaneous route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0537-1482
Description: Administered via subcutaneous route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered via subcutaneous route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered via subcutaneous route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered via subcutaneous route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered via subcutaneous route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered via subcutaneous route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered via subcutaneous route

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via subcutaneous route
Study: NCT06624696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride
Description: The penehyclidine hydrochloride will be diluted to a total volume of 5 mL with normal saline, added to the nebulizer cup for inhalation. Patients will be asked to inhale the entire volume of nebulized drugs within 30 min prior to surgery. The trial drugs will be administered using a jet nebulizer with compressed air flow. Each child will be intructed to begin the nebulization by using a face mask that covers the nose and mouth while the child is seated upright. Children will be encouraged to take deep and slow breaths, inhaling through the mouth and exhaling through the nose, to ensure the drugs effectively reaches the airway.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: The normal saline with a total volume of 5 mL will be added to the nebulizer cup for inhalation. Patients will be asked to inhale the entire volume of nebulized drugs within 30 min prior to surgery. The trial drugs will be administered using a jet nebulizer with compressed air flow. Each child will be intructed to begin the nebulization by using a face mask that covers the nose and mouth while the child is seated upright. Children will be encouraged to take deep and slow breaths, inhaling through the mouth and exhaling through the nose, to ensure the drugs effectively reaches the airway.
Study: NCT04841577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSVPreF3 OA investigational vaccine
Description: RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLU-QIV
Description: FLU-QIV administered intramuscularly in the deltoid region of the dominant (Co-Ad Group) arm or the non-dominant (Control Group) arm.
Study: NCT05562609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Ampoules and packaging for all arms will be identical in appearance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Ampoules and packaging for all arms will be identical in appearance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ampoules and packaging for all arms will be identical in appearance.
Study: NCT06756165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental health screening
Description: Participants in the intervention arm will receive a mental health screening and referral program conducted by trained Lady Health Workers (LHWs). The program includes:~Mental Health Screening:~LHWs will screen participants using a validated, mental health tool during participants' routine visits.~Referral to Local Health Facilities:~Women identified with mental health concerns during the screening process will be referred to local healthcare facilities.~Group Awareness and Resilience-Building Sessions:~LHWs will facilitate group sessions to improve mental health awareness and build resilience, including resilience to climate change-related hazards such as floods, within the community.~This arm is designed to evaluate the feasibility, acceptability, and appropriateness of implementing a community-based mental health screening, referral, and resilience-building program through LHW in a flood-affected rural community in Sindh, Pakistan.
Study: NCT06757725

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: colour doppler of the renal artery and measurement of resistive index
Description: using colour doppler to asses vascular resistance and resistive index

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: colour doppler of the renal artery and measurement of resistive index
Description: using colour doppler to asses vascular resistance and resistive index
Study: NCT05537571

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride, solution for injection
Study: NCT06756711

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A combination of apitherapy and plant extracts
Description: This combination contains the active comparator

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Combination
Description: A combination containing inert substances - placebo
Study: NCT06757153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRG-103
Description: NRG-103 is an oncolytic virus, which can kill GBM cells via three manners.
Study: NCT06758232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: It will consist of sessions that include neck anatomy, biomechanics, proper posture, ergonomics and neck exercise training.
Study: NCT06757179

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elysium Naso Gola
Description: Elysium Naso Gola Supplement is a dietary supplement designed to soothe the upper respiratory tract, providing a range of benefits thanks to the properties of its natural ingredients. Its anti-inflammatory, antibacterial, antifungal, antiviral, antioxidant, and prebiotic activities suggest a comprehensive product for supporting respiratory health.~Mullein promotes the functionality of the respiratory mucous membranes. Thyme supports nasal and throat well-being, aids in the fluidity of bronchial secretions, and has antioxidant properties.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06756828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 3months melatonin

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy group for insomnia
Description: 15minutes of sleep hygiene education on the first day of visiting the hospital
Study: NCT06756841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEF treatment
Description: PEF energy delivery via endoscope
Study: NCT05562609

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Ampoules and packaging for all arms will be identical in appearance.
Study: NCT06757790

Intervention type: OTHER
Intervention: A comparison between primary ceaseran section women and primary vaginally delivery women to determine predictors of primary ceaseran section
Description: A comparison between primary ceaseran section women and primary vaginally delivery women to determine predictors of primary ceaseran section

Intervention type: OTHER
Intervention: A comparison between primary ceaseran section women and primary vaginally delivery women to determine predictors of primary ceaseran section
Description: A comparison between primary ceaseran section women and primary vaginally delivery women to determine predictors of primary ceaseran section
Study: NCT06756932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-21447
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-21447
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered via intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered via intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-43395
Description: Administered orally.
Study: NCT04841577

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLU-QIV
Description: FLU-QIV administered intramuscularly in the deltoid region of the dominant (Co-Ad Group) arm or the non-dominant (Control Group) arm.
Study: NCT04891003

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: The identification of optimal ultrasonografic tecniques for determining the location , size and the surgical methods of intestinal endometriotric nodules.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: The identification of optimal ultrasonografic tecniques for determining the location , size and the surgical methods of intestinal endometriotric nodules.
Study: NCT06630000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT
Description: Two 90-minute FACT sessions led by a trained interventionist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Two 90-minute sessions individually with a study interventionist, 2-weeks apart (focused on nutrition education).
Study: NCT04944901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-121
Description: SB-121 is a formulation of L. reuteri

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral formulation
Study: NCT05562609

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ampoules and packaging for all arms will be identical in appearance.
Study: NCT06356389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JX11502MA
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT06287398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab (Epcor) is a bispecific antibody recognizing the T-cell antigen CD3 and the B-cell antigen CD20. Epcor is a supplied as a concentrate for solution for intended subcutaneous injection. The dose must be prepared by a qualified pharmacist using aseptic technique.~Epcoritamab-Salvage treatment phase:~2-3 cycles of R-DHAOx therapy (rituximab, dexamethasone, cytarabine, oxaliplatin), given every 21 days combined with Epcoritamab subcutaneous weekly dosing (priming 0.16mg Cycle 1 Day 1, intermediate 0.8mg cycle 1 day 8, full dose 48mg from cycle 1 day 15 onwards)~Epcoritamab Consolidation phase:~6 cycles (28 days each) of subcutaneous Epcoritamab, commencing between 6-12 weeks post ASCT.~Epcoritamab dosing and timing for consolidation:~* Cycle 1 Day 1: Priming (0.16mg) dose~* Cycle 1 Day 8: intermediate (0.8mg) dose~* Cycle 1 Day 15: full dose 48mg~* Cycle 1 Day 22, Cycle 2-3 Days 1, 8, 15 and 22: 48mg~* Cycles 4 to 6 - Days 1 and 15 (fortnightly dosing): 48mg
Study: NCT04710615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synapse platform
Description: The Synapse platform made available to health professionals, is a virtual assistant capable of understanding the questions of natural language doctors and providing an answer by specifying the source of information used. This device also allows you to photograph a prescription and analyze it automatically to detect potential drug interactions.~The Synapse platform offers a panel of functions to help the doctor to prescribe medication.